{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T07:18:14Z","timestamp":1789975094730,"version":"4.0.1"},"reference-count":358,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2018,12,2]],"date-time":"2018-12-02T00:00:00Z","timestamp":1543708800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100010221","name":"Higher Education Commision, Pakistan","doi-asserted-by":"publisher","award":["20\u20103629\/NRPU\/R&D\/HEC\/14\/585"],"award-info":[{"award-number":["20\u20103629\/NRPU\/R&D\/HEC\/14\/585"]}],"id":[{"id":"10.13039\/501100010221","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Medicinal Research Reviews"],"published-print":{"date-parts":[[2019,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Hepatitis C compromises the quality of life of more than 350 million individuals worldwide. Over the last decade, therapeutic regimens for treating hepatitis C virus (HCV) infections have undergone rapid advancements. Initially, structure\u2010based drug design was used to develop molecules that inhibit viral enzymes. Subsequently, establishment of cell\u2010based replicon systems enabled investigations into various stages of HCV life cycle including its entry, replication, translation, and assembly, as well as role of host proteins. Collectively, these approaches have facilitated identification of important molecules that are deemed essential for HCV life cycle. The expanded set of putative virus and host\u2010encoded targets has brought us one step closer to developing robust strategies for efficacious, pangenotypic, and well\u2010tolerated medicines against HCV. Herein, we provide an overview of the development of various classes of virus and host\u2010directed therapies that are currently in use along with others that are undergoing clinical evaluation.<\/jats:p>","DOI":"10.1002\/med.21554","type":"journal-article","created":{"date-parts":[[2018,12,3]],"date-time":"2018-12-03T02:18:31Z","timestamp":1543803511000},"page":"1091-1136","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Evolution of efficacious pangenotypic hepatitis C virus therapies"],"prefix":"10.1002","volume":"39","author":[{"given":"Muhammad Usman","family":"Ashraf","sequence":"first","affiliation":[{"name":"Biomedical Informatics Research Laboratory, Department of Biology Lahore University of Management Sciences Lahore Pakistan"},{"name":"Virology Laboratory, Center of Excellence in Molecular Biology, University of the Punjab Lahore Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanzal","family":"Iman","sequence":"additional","affiliation":[{"name":"Biomedical Informatics Research Laboratory, Department of Biology Lahore University of Management Sciences Lahore Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Farhan","family":"Khalid","sequence":"additional","affiliation":[{"name":"Biomedical Informatics Research Laboratory, Department of Biology Lahore University of Management Sciences Lahore Pakistan"},{"name":"Department of Biomedical Engineering University of Engineering and Technology Lahore Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hafiz Muhammad","family":"Salman","sequence":"additional","affiliation":[{"name":"Biomedical Informatics Research Laboratory, Department of Biology Lahore University of Management Sciences Lahore Pakistan"},{"name":"Plant Biotechnology Laboratory, Institute of Agricultural Sciences, University of the Punjab Lahore Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talha","family":"Shafi","sequence":"additional","affiliation":[{"name":"Biomedical Informatics Research Laboratory, Department of Biology Lahore University of Management Sciences Lahore Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Momal","family":"Rafi","sequence":"additional","affiliation":[{"name":"Department of Statistics University of Gujrat Gujrat Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nida","family":"Javaid","sequence":"additional","affiliation":[{"name":"Department of Biology Lahore University of Management Sciences Lahore Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashid","family":"Hussain","sequence":"additional","affiliation":[{"name":"Biomedical Informatics Research Laboratory, Department of Biology Lahore University of Management Sciences Lahore Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fayyaz","family":"Ahmad","sequence":"additional","affiliation":[{"name":"Department of Statistics University of Gujrat Gujrat Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed","family":"Shahzad\u2010Ul\u2010Hussan","sequence":"additional","affiliation":[{"name":"Department of Biology Lahore University of Management Sciences Lahore Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaper","family":"Mirza","sequence":"additional","affiliation":[{"name":"Department of Biology Lahore University of Management Sciences Lahore Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Shafiq","sequence":"additional","affiliation":[{"name":"Plant Biotechnology Laboratory, Institute of Agricultural Sciences, University of the Punjab Lahore Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samia","family":"Afzal","sequence":"additional","affiliation":[{"name":"Virology Laboratory, Center of Excellence in Molecular Biology, University of the Punjab Lahore Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadia","family":"Hamera","sequence":"additional","affiliation":[{"name":"Department of Plant Genetics, Institute of Life Sciences, University of Rostock Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saima","family":"Anwar","sequence":"additional","affiliation":[{"name":"Department of Biomedical Engineering University of Engineering and Technology Lahore Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romena","family":"Qazi","sequence":"additional","affiliation":[{"name":"Department of Pathology Shaukat Khanum Memorial Cancer Hospital &amp; Research Centre Lahore Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Idrees","sequence":"additional","affiliation":[{"name":"Virology Laboratory, Center of Excellence in Molecular Biology, University of the Punjab Lahore Pakistan"},{"name":"Hazara University Mansehra Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sohail A.","family":"Qureshi","sequence":"additional","affiliation":[{"name":"Institute of Integrative Biosciences, CECOS\u2010University of Information Technology and Emerging Sciences Peshawar Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3758-6581","authenticated-orcid":false,"given":"Safee Ullah","family":"Chaudhary","sequence":"additional","affiliation":[{"name":"Biomedical Informatics Research Laboratory, Department of Biology Lahore University of Management Sciences Lahore Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,12,2]]},"reference":[{"key":"e_1_2_6_1_2_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v22.i34.7824"},{"key":"e_1_2_6_1_3_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.2523562"},{"key":"e_1_2_6_1_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26744"},{"key":"e_1_2_6_1_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-27340-7_5"},{"key":"e_1_2_6_1_6_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1003355"},{"key":"e_1_2_6_1_7_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1001278"},{"key":"e_1_2_6_1_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2010.04.015"},{"key":"e_1_2_6_1_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/20.14.3840"},{"key":"e_1_2_6_1_10_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0158419"},{"key":"e_1_2_6_1_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/00001610-199108000-00012"},{"key":"e_1_2_6_1_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198612183152503"},{"key":"e_1_2_6_1_13_1","doi-asserted-by":"crossref","first-page":"36S121","DOI":"10.1002\/hep.1840360716","article-title":"Optimal therapy of hepatitis C","volume":"36","author":"Di Bisceglie AM","year":"2002","journal-title":"Hepatology"},{"issue":"1","key":"e_1_2_6_1_14_1","first-page":"57","article-title":"Combination therapy with interferon plus ribavirin for the initial treatment of chronic hepatitis C","volume":"19","author":"McHutchison JG","year":"1999","journal-title":"Semi Liver Dis"},{"key":"e_1_2_6_1_15_1","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2000.110973"},{"key":"e_1_2_6_1_16_1","doi-asserted-by":"publisher","DOI":"10.4103\/1119-3077.173708"},{"key":"e_1_2_6_1_17_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01480"},{"key":"e_1_2_6_1_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm1353"},{"key":"e_1_2_6_1_19_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2335981100"},{"key":"e_1_2_6_1_20_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.26.15394"},{"key":"e_1_2_6_1_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jviromet.2013.01.003"},{"key":"e_1_2_6_1_22_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01256-12"},{"key":"e_1_2_6_1_23_1","doi-asserted-by":"publisher","DOI":"10.1099\/vir.0.81334-0"},{"key":"e_1_2_6_1_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm1268"},{"key":"e_1_2_6_1_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature03580"},{"key":"e_1_2_6_1_26_1","doi-asserted-by":"publisher","DOI":"10.1021\/acschembio.5b00647"},{"key":"e_1_2_6_1_27_1","doi-asserted-by":"publisher","DOI":"10.1039\/C6MD00636A"},{"key":"e_1_2_6_1_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature02099"},{"key":"e_1_2_6_1_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.2020"},{"key":"e_1_2_6_1_30_1","doi-asserted-by":"publisher","DOI":"10.4103\/0976-500X.142464"},{"key":"e_1_2_6_1_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/lt.24349"},{"key":"e_1_2_6_1_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2012.10.009"},{"key":"e_1_2_6_1_33_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2013-306155"},{"key":"e_1_2_6_1_34_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00016-14"},{"key":"e_1_2_6_1_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-016-0558-3"},{"key":"e_1_2_6_1_36_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1208953"},{"key":"e_1_2_6_1_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13027"},{"key":"e_1_2_6_1_38_1","doi-asserted-by":"publisher","DOI":"10.3390\/v7112902"},{"key":"e_1_2_6_1_39_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.88.8.3392"},{"key":"e_1_2_6_1_40_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.12.060"},{"key":"e_1_2_6_1_41_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.06.002"},{"key":"e_1_2_6_1_42_1","unstructured":"Hepatitis B and C Treatments.https:\/\/www.fda.gov\/forpatients\/illness\/hepatitisbc\/ucm408658.htm. Accessed November 18 2018."},{"key":"e_1_2_6_1_43_1","unstructured":"R\u2010pharm rolls out new tablet for treatment of hepatitis C | Evaluate.http:\/\/www.r-pharm.com\/en\/press-center\/news\/290. Accessed November 18 2018."},{"key":"e_1_2_6_1_44_1","doi-asserted-by":"publisher","DOI":"10.1002\/pro.2378"},{"key":"e_1_2_6_1_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)81350-1"},{"key":"e_1_2_6_1_46_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.5.1813-1822.2006"},{"key":"e_1_2_6_1_47_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0087077"},{"key":"e_1_2_6_1_48_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199604183341602"},{"key":"e_1_2_6_1_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-894X(98)00299-6"},{"key":"e_1_2_6_1_50_1","doi-asserted-by":"publisher","DOI":"10.1021\/bi980313v"},{"key":"e_1_2_6_1_51_1","doi-asserted-by":"publisher","DOI":"10.1021\/jo010164d"},{"key":"e_1_2_6_1_52_1","doi-asserted-by":"publisher","DOI":"10.1021\/bi980314n"},{"issue":"8","key":"e_1_2_6_1_53_1","doi-asserted-by":"crossref","first-page":"6758","DOI":"10.1128\/JVI.72.8.6758-6769.1998","article-title":"Multiple enzymatic activities associated with recombinant NS3 protein of hepatitis C virus","volume":"72","author":"Gallinari P","year":"1998","journal-title":"J Virol"},{"key":"e_1_2_6_1_54_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm0342414"},{"key":"e_1_2_6_1_55_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm100690x"},{"key":"e_1_2_6_1_56_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1099-1387(200001)6:1<11::AID-PSC229>3.0.CO;2-#"},{"key":"e_1_2_6_1_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2004.01.022"},{"key":"e_1_2_6_1_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-894X(00)00074-3"},{"key":"e_1_2_6_1_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2004.07.007"},{"issue":"1369","key":"e_1_2_6_1_60_1","first-page":"57","article-title":"Telaprevir (Incivek) and boceprevir (Victrelis) for chronic hepatitis C","volume":"53","journal-title":"Med Lett Drugs Ther"},{"key":"e_1_2_6_1_61_1","doi-asserted-by":"publisher","DOI":"10.1021\/ml9000276"},{"issue":"12","key":"e_1_2_6_1_62_1","doi-asserted-by":"crossref","first-page":"7098","DOI":"10.1128\/AAC.01044-16","article-title":"Pharmacokinetics of the new hepatitis C virus NS3 protease inhibitor narlaprevir following single\u2010dose use with or without ritonavir in patients with liver cirrhosis","volume":"60","author":"Isakov V","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"e_1_2_6_1_63_1","first-page":"41","article-title":"Efficacy and safety of the Russian protease inhibitor narlaprevir at treatment\u2010naive and earlier treated noncirrhotic patients with the 1st genotype chronic hepatitis C (PIONEER study)","volume":"27","author":"Mayevskaya MV","year":"2017","journal-title":"Russ J Gastroenterol Hepatol Coloproctology"},{"key":"e_1_2_6_1_64_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm401840s"},{"key":"e_1_2_6_1_65_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm500297k"},{"key":"e_1_2_6_1_66_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm100690x"},{"key":"e_1_2_6_1_67_1","doi-asserted-by":"publisher","DOI":"10.1039\/C4OB00738G"},{"key":"e_1_2_6_1_68_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2007.07.007"},{"key":"e_1_2_6_1_69_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2004.08.002"},{"key":"e_1_2_6_1_70_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm9015526"},{"key":"e_1_2_6_1_71_1","doi-asserted-by":"publisher","DOI":"10.1021\/acsmedchemlett.5b00425"},{"key":"e_1_2_6_1_72_1","doi-asserted-by":"publisher","DOI":"10.1021\/ml400466p"},{"key":"e_1_2_6_1_73_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12527"},{"key":"e_1_2_6_1_74_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1006370107"},{"issue":"44","key":"e_1_2_6_1_75_1","doi-asserted-by":"crossref","first-page":"36784","DOI":"10.1074\/jbc.M506462200","article-title":"In vitro studies of cross\u2010resistance mutations against two hepatitis C virus serine protease inhibitors, VX\u2010950 and BILN 2061","volume":"280","author":"Lin C","journal-title":"J Biol Chem"},{"key":"e_1_2_6_1_76_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01149-07"},{"key":"e_1_2_6_1_77_1","first-page":"32A","volume-title":"Hepatology","author":"Lahser F","year":"2016"},{"key":"e_1_2_6_1_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(15)30071-4"},{"key":"e_1_2_6_1_79_1","first-page":"62563A","article-title":"Resistance analysis of Treatment\u2010na\u00efve and DAA\u2010experienced Genotype 1 Patients with and without Cirrhosis Who Received Short\u2010duration Treatment with Sofosbuvir\/gs\u20105816\u2009+\u2009Gs\u20109857: 713","author":"Gane EJ","year":"2015","journal-title":"Hepatology"},{"key":"e_1_2_6_1_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2011.08.015"},{"key":"e_1_2_6_1_81_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2011.11.007"},{"key":"e_1_2_6_1_82_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.67.10.6152-6158.1993"},{"key":"e_1_2_6_1_83_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.273.24.15045"},{"key":"e_1_2_6_1_84_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm8011905"},{"key":"e_1_2_6_1_85_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1432-1033.2003.03540.x"},{"key":"e_1_2_6_1_86_1","doi-asserted-by":"publisher","DOI":"10.1093\/jb\/mvg167"},{"key":"e_1_2_6_1_87_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01534-07"},{"key":"e_1_2_6_1_88_1","doi-asserted-by":"publisher","DOI":"10.1021\/acschembio.5b00101"},{"key":"e_1_2_6_1_89_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.77.9.5428-5438.2003"},{"key":"e_1_2_6_1_90_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3000331"},{"key":"e_1_2_6_1_91_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.76.12.5974-5984.2002"},{"key":"e_1_2_6_1_92_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.77.9.5487-5492.2003"},{"key":"e_1_2_6_1_93_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.1490"},{"key":"e_1_2_6_1_94_1","doi-asserted-by":"publisher","DOI":"10.1086\/653080"},{"key":"e_1_2_6_1_95_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2010.03.013"},{"key":"e_1_2_6_1_96_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00527-13"},{"key":"e_1_2_6_1_97_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00813-15"},{"key":"e_1_2_6_1_98_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M008329200"},{"key":"e_1_2_6_1_99_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.78.6.2738-2748.2004"},{"key":"e_1_2_6_1_100_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M407787200"},{"key":"e_1_2_6_1_101_1","doi-asserted-by":"publisher","DOI":"10.1099\/vir.0.80204-0"},{"key":"e_1_2_6_1_102_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm401836p"},{"key":"e_1_2_6_1_103_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm500335h"},{"key":"e_1_2_6_1_104_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306218"},{"key":"e_1_2_6_1_105_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2014-307498"},{"key":"e_1_2_6_1_106_1","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.1994.2667"},{"key":"e_1_2_6_1_107_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00253-11"},{"key":"e_1_2_6_1_108_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.04.021"},{"key":"e_1_2_6_1_109_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1203110110"},{"key":"e_1_2_6_1_110_1","doi-asserted-by":"crossref","first-page":"44765","DOI":"10.1038\/srep04765","article-title":"Potent hepatitis C inhibitors bind directly to NS5A and reduce its affinity for RNA","volume":"4","author":"Ascher DB","year":"2014","journal-title":"Sci Rep"},{"key":"e_1_2_6_1_111_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.07.019"},{"key":"e_1_2_6_1_112_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02352-08"},{"key":"e_1_2_6_1_113_1","doi-asserted-by":"publisher","DOI":"10.1002\/pro.2456"},{"key":"e_1_2_6_1_114_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm501291c"},{"key":"e_1_2_6_1_115_1","doi-asserted-by":"publisher","DOI":"10.3390\/genes9070343"},{"key":"e_1_2_6_1_116_1","doi-asserted-by":"publisher","DOI":"10.1021\/ci400631n"},{"key":"e_1_2_6_1_117_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm4013104"},{"key":"e_1_2_6_1_118_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2013.06.032"},{"key":"e_1_2_6_1_119_1","first-page":"741","article-title":"Approaches to hepatitis C treatment and cure using NS5A inhibitors","volume":"7","author":"Kohler JJ","year":"2014","journal-title":"Infect Drug Resist"},{"key":"e_1_2_6_1_120_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro3046"},{"key":"e_1_2_6_1_121_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12615"},{"key":"e_1_2_6_1_122_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.03.014"},{"key":"e_1_2_6_1_123_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.01.007"},{"key":"e_1_2_6_1_124_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.09.011"},{"key":"e_1_2_6_1_125_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04226-14"},{"key":"e_1_2_6_1_126_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(13)61210-6"},{"key":"e_1_2_6_1_127_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02193-12"},{"key":"e_1_2_6_1_128_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.10.017"},{"key":"e_1_2_6_1_129_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2011.12.029"},{"key":"e_1_2_6_1_130_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0122844"},{"key":"e_1_2_6_1_131_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.04.003"},{"key":"e_1_2_6_1_132_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.74.2.851-863.2000"},{"key":"e_1_2_6_1_133_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00386-12"},{"key":"e_1_2_6_1_134_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.23.13034"},{"key":"e_1_2_6_1_135_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.71.11.8416-8428.1997"},{"key":"e_1_2_6_1_136_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198707233170401"},{"key":"e_1_2_6_1_137_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02395-06"},{"key":"e_1_2_6_1_138_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198406143102401"},{"key":"e_1_2_6_1_139_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.21047"},{"key":"e_1_2_6_1_140_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M210891200"},{"key":"e_1_2_6_1_141_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.78.2.938-946.2004"},{"key":"e_1_2_6_1_142_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M506407200"},{"key":"e_1_2_6_1_143_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm201384j"},{"key":"e_1_2_6_1_144_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2014.04.005"},{"key":"e_1_2_6_1_145_1","doi-asserted-by":"publisher","DOI":"10.3390\/v2102169"},{"key":"e_1_2_6_1_146_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0148181"},{"key":"e_1_2_6_1_147_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2010.05.030"},{"key":"e_1_2_6_1_148_1","doi-asserted-by":"publisher","DOI":"10.1021\/ci9004749"},{"key":"e_1_2_6_1_149_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2012.04.016"},{"key":"e_1_2_6_1_150_1","doi-asserted-by":"publisher","DOI":"10.1021\/ci400644r"},{"key":"e_1_2_6_1_151_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.12068"},{"key":"e_1_2_6_1_152_1","doi-asserted-by":"publisher","DOI":"10.3181\/00379727-109-27169"},{"key":"e_1_2_6_1_153_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(62)90225-3"},{"key":"e_1_2_6_1_154_1","unstructured":"ReddyI AlEAntiviral activity pharmacokinetics safety and tolerability of R7128 a novel nucleoside HCV RNA polymerase inhibitor following multiple ascending oral doses in patients with HCV genotype 1 infection who have failed prior interferon therapy. In: Annual Meeting of the American Association. Boston USA2007."},{"key":"e_1_2_6_1_155_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(08)60068-9"},{"key":"e_1_2_6_1_156_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M110.161802"},{"key":"e_1_2_6_1_157_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu697"},{"key":"e_1_2_6_1_158_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27375"},{"key":"e_1_2_6_1_159_1","unstructured":"Vertex Pharmaceuticals Incorporated. Vertex provides update on ongoing all\u2010oral studies of VX\u2010135 in hepatitis C. (2013).https:\/\/investors.vrtx.com\/news\u2010releases\/news\u2010release\u2010details\/vertex\u2010provides\u2010update\u2010ongoing\u2010all\u2010oral\u2010studies\u2010vx\u2010135\u2010hepatitis(2013)."},{"key":"e_1_2_6_1_160_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2011.10.001"},{"key":"e_1_2_6_1_161_1","doi-asserted-by":"publisher","DOI":"10.2174\/157340708785294217"},{"key":"e_1_2_6_1_162_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M209397200"},{"key":"e_1_2_6_1_163_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm060269e"},{"key":"e_1_2_6_1_164_1","first-page":"142","article-title":"Viekira Pak (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets): all\u2010oral fixed combination approved for genotype 1 chronic hepatitis C infection. Am Heal Drug Benefits","volume":"8","author":"Raedler LA","year":"2015","journal-title":"Am Health Drug Benefits"},{"key":"e_1_2_6_1_165_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0157438"},{"key":"e_1_2_6_1_166_1","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.12685"},{"key":"e_1_2_6_1_167_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1401561"},{"key":"e_1_2_6_1_168_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1315722"},{"key":"e_1_2_6_1_169_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.10.057"},{"key":"e_1_2_6_1_170_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02579-13"},{"key":"e_1_2_6_1_171_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.virusres.2006.02.004"},{"key":"e_1_2_6_1_172_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M209732200"},{"key":"e_1_2_6_1_173_1","doi-asserted-by":"publisher","DOI":"10.1186\/1743-422X-3-66"},{"key":"e_1_2_6_1_174_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.01.055"},{"key":"e_1_2_6_1_175_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23281"},{"key":"e_1_2_6_1_176_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2015.02.005"},{"key":"e_1_2_6_1_177_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2015.10.001"},{"key":"e_1_2_6_1_178_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0915117107"},{"key":"e_1_2_6_1_179_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0912966107"},{"key":"e_1_2_6_1_180_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12250-010-3134-0"},{"key":"e_1_2_6_1_181_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.76.24.13001-13014.2002"},{"key":"e_1_2_6_1_182_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.15.3472"},{"key":"e_1_2_6_1_183_1","doi-asserted-by":"publisher","DOI":"10.3851\/IMP2023"},{"key":"e_1_2_6_1_184_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt1207-1383"},{"issue":"1","key":"e_1_2_6_1_185_1","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/msb.2008.66","article-title":"Hepatitis C virus infection protein network","volume":"4","author":"Chassey B","year":"2008","journal-title":"Mol Syst Biol"},{"key":"e_1_2_6_1_186_1","doi-asserted-by":"publisher","DOI":"10.1039\/c0mb00103a"},{"key":"e_1_2_6_1_187_1","doi-asserted-by":"publisher","DOI":"10.1021\/pr3011217"},{"key":"e_1_2_6_1_188_1","doi-asserted-by":"publisher","DOI":"10.1039\/c3mb70343f"},{"key":"e_1_2_6_1_189_1","doi-asserted-by":"publisher","DOI":"10.1074\/mcp.M113.030155"},{"key":"e_1_2_6_1_190_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2014.12.028"},{"key":"e_1_2_6_1_191_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.virusres.2015.12.003"},{"key":"e_1_2_6_1_192_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22547"},{"key":"e_1_2_6_1_193_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2012.02.018"},{"key":"e_1_2_6_1_194_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.3179"},{"key":"e_1_2_6_1_195_1","unstructured":"Ezetimibe.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2002\/21445_Zetia.cfm"},{"issue":"5","key":"e_1_2_6_1_196_1","first-page":"789","article-title":"Biological response modifiers","volume":"70","author":"Oldham RK","year":"1983","journal-title":"J Natl Cancer Inst"},{"key":"e_1_2_6_1_197_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2016-1209"},{"key":"e_1_2_6_1_198_1","doi-asserted-by":"publisher","DOI":"10.1038\/256495a0"},{"key":"e_1_2_6_1_199_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(84)90097-4"},{"key":"e_1_2_6_1_200_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198411293112205"},{"issue":"2","key":"e_1_2_6_1_201_1","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1155\/1991\/782768","article-title":"The potential role of recombinant hematopoietic colony\u2010stimulating factors in preventing infections in the immunocompromised host","volume":"2","author":"Rusthoven J","year":"1991","journal-title":"Can J Infect Dis Med Microbiol"},{"key":"e_1_2_6_1_202_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23743"},{"key":"e_1_2_6_1_203_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0164563"},{"key":"e_1_2_6_1_204_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21773"},{"key":"e_1_2_6_1_205_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2011.04745.x"},{"issue":"11","key":"e_1_2_6_1_206_1","first-page":"571","article-title":"Thymosin alpha 1 in combination with interferon alpha and ribavirin in chronic hepatitis C patients who are non\u2010responders or relapsers to interferon alpha plus ribavirin","volume":"54","author":"Abbas Z","year":"2004","journal-title":"J Pak Med Assoc"},{"key":"e_1_2_6_1_207_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.7.7.953"},{"key":"e_1_2_6_1_208_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.12267"},{"key":"e_1_2_6_1_209_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M302267200"},{"key":"e_1_2_6_1_210_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-9071(199903)57:3<223::AID-JMV2>3.0.CO;2-4"},{"key":"e_1_2_6_1_211_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02199-08"},{"key":"e_1_2_6_1_212_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.282.5390.938"},{"key":"e_1_2_6_1_213_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature07684"},{"key":"e_1_2_6_1_214_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature05654"},{"key":"e_1_2_6_1_215_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00024-06"},{"key":"e_1_2_6_1_216_1","doi-asserted-by":"publisher","DOI":"10.1039\/C4NR03875D"},{"key":"e_1_2_6_1_217_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M602431200"},{"key":"e_1_2_6_1_218_1","doi-asserted-by":"publisher","DOI":"10.3390\/v4102016"},{"key":"e_1_2_6_1_219_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1005368"},{"key":"e_1_2_6_1_220_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1002895"},{"key":"e_1_2_6_1_221_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23445"},{"key":"e_1_2_6_1_222_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27276"},{"key":"e_1_2_6_1_223_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00750-12"},{"key":"e_1_2_6_1_224_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2341"},{"key":"e_1_2_6_1_225_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-009-0132-9"},{"key":"e_1_2_6_1_226_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jit503"},{"key":"e_1_2_6_1_227_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0500269102"},{"key":"e_1_2_6_1_228_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2581"},{"key":"e_1_2_6_1_229_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0300-9084(03)00004-X"},{"key":"e_1_2_6_1_230_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00127-07"},{"key":"e_1_2_6_1_231_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0405695101"},{"key":"e_1_2_6_1_232_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00633-11"},{"key":"e_1_2_6_1_233_1","doi-asserted-by":"publisher","DOI":"10.1021\/mp400399b"},{"key":"e_1_2_6_1_234_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2007.04.008"},{"issue":"8","key":"e_1_2_6_1_235_1","first-page":"860","article-title":"Celgosivir, an alpha\u2010glucosidase I inhibitor for the potential treatment of HCV infection","volume":"10","author":"Durantel D","year":"2009","journal-title":"Curr Opin Investig Drugs"},{"key":"e_1_2_6_1_236_1","first-page":"1","volume-title":"Methods in Enzymology","author":"Pan S","year":"2011"},{"key":"e_1_2_6_1_237_1","first-page":"pp. 111","volume-title":"Macsween's Pathology of the Liver","author":"Quaglia A"},{"key":"e_1_2_6_1_238_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2004.09.038"},{"key":"e_1_2_6_1_239_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1113329"},{"key":"e_1_2_6_1_240_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1178178"},{"key":"e_1_2_6_1_241_1","first-page":"11153","article-title":"Long\u2010term safety and efficacy of microRNA\u2010targeted therapy in chronic hepatitis C patients","volume":"111","author":"Ree MH","year":"2014","journal-title":"Antivir Res"},{"key":"e_1_2_6_1_242_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31715-9"},{"key":"e_1_2_6_1_243_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2014.10.041"},{"key":"e_1_2_6_1_244_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1003359"},{"key":"e_1_2_6_1_245_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02418-08"},{"key":"e_1_2_6_1_246_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00303-13"},{"key":"e_1_2_6_1_247_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00939-08"},{"key":"e_1_2_6_1_248_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00660-09"},{"key":"e_1_2_6_1_249_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature12427"},{"key":"e_1_2_6_1_250_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2010.01.041"},{"key":"e_1_2_6_1_251_1","doi-asserted-by":"publisher","DOI":"10.3390\/v4112558"},{"key":"e_1_2_6_1_252_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00310-06"},{"key":"e_1_2_6_1_253_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22131"},{"key":"e_1_2_6_1_254_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0121608"},{"key":"e_1_2_6_1_255_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2015.04.016"},{"issue":"1","key":"e_1_2_6_1_256_1","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1128\/jvi.71.1.697-704.1997","article-title":"Formation of native hepatitis C virus glycoprotein complexes","volume":"71","author":"Deleersnyder V","year":"1997","journal-title":"J Virol"},{"key":"e_1_2_6_1_257_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02053-07"},{"key":"e_1_2_6_1_258_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncb1631"},{"key":"e_1_2_6_1_259_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2238"},{"key":"e_1_2_6_1_260_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3190"},{"key":"e_1_2_6_1_261_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2015.03.012"},{"key":"e_1_2_6_1_262_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.22.12766"},{"key":"e_1_2_6_1_263_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0700760104"},{"key":"e_1_2_6_1_264_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2011.02.011"},{"key":"e_1_2_6_1_265_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26634"},{"key":"e_1_2_6_1_266_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02068-13"},{"key":"e_1_2_6_1_267_1","doi-asserted-by":"publisher","DOI":"10.1098\/rspb.1957.0048"},{"key":"e_1_2_6_1_268_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2006.08.007"},{"key":"e_1_2_6_1_269_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2006.08.014"},{"key":"e_1_2_6_1_270_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.2523562"},{"key":"e_1_2_6_1_271_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198911303212203"},{"key":"e_1_2_6_1_272_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840160307"},{"key":"e_1_2_6_1_273_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.1890460110"},{"key":"e_1_2_6_1_274_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199506013322201"},{"issue":"1","key":"e_1_2_6_1_275_1","first-page":"56","article-title":"Serious side\u2010effects of interferon alfa and ribavirin combination therapy in patients with chronic hepatitis C","volume":"48","author":"Str\u00e1nsk\u00fd J","year":"2002","journal-title":"Vnitr Lek"},{"key":"e_1_2_6_1_276_1","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2001.26371"},{"key":"e_1_2_6_1_277_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200012073432301"},{"issue":"4","key":"e_1_2_6_1_278_1","first-page":"655","article-title":"Using pegylated interferon and ribavirin to treat patients with chronic hepatitis C","volume":"72","author":"Ward RP","year":"2005","journal-title":"Am Fam Physician"},{"key":"e_1_2_6_1_279_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1012912"},{"key":"e_1_2_6_1_280_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1010494"},{"key":"e_1_2_6_1_281_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1013086"},{"key":"e_1_2_6_1_282_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.10.058"},{"key":"e_1_2_6_1_283_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60538-9"},{"key":"e_1_2_6_1_284_1","unstructured":"Gilead SciencesIUS food and drug administration approves gilead\u2019s Sovaldi\u2122 (sofosbuvir) for the treatment of chronic hepatitis C.http:\/\/www.gilead.com\/news\/press\u2010releases\/2013\/12\/us\u2010food\u2010and\u2010drug\u2010administration\u2010approves\u2010gileads\u2010sovaldi\u2010sofosbuvir\u2010for\u2010the\u2010treatment\u2010of\u2010chronic\u2010hepatitis\u2010c(2013)."},{"key":"e_1_2_6_1_285_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1214853"},{"key":"e_1_2_6_1_286_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1214854"},{"issue":"48","key":"e_1_2_6_1_287_1","first-page":"1619","article-title":"Prospective study of a high\u2010intensity interferon\u2010alpha regimen for chronic hepatitis C virus genotype 1b infection","volume":"49","author":"Toyoda H","year":"2002","journal-title":"Hepatogastroenterology"},{"key":"e_1_2_6_1_288_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(03)00391-X"},{"key":"e_1_2_6_1_289_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)06102-5"},{"key":"e_1_2_6_1_290_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020047"},{"key":"e_1_2_6_1_291_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27567"},{"key":"e_1_2_6_1_292_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61384-0"},{"key":"e_1_2_6_1_293_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1104430"},{"key":"e_1_2_6_1_294_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24724"},{"key":"e_1_2_6_1_295_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29671"},{"key":"e_1_2_6_1_296_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29358"},{"key":"e_1_2_6_1_297_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61036-9"},{"key":"e_1_2_6_1_298_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(15)30168-9"},{"key":"e_1_2_6_1_299_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(15)30158-6"},{"key":"e_1_2_6_1_300_1","doi-asserted-by":"publisher","DOI":"10.7448\/IAS.17.4.19741"},{"key":"e_1_2_6_1_301_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.08.051"},{"key":"e_1_2_6_1_302_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.12693"},{"key":"e_1_2_6_1_303_1","first-page":"56569A","article-title":"SOUND\u2010C2: SVR4, 12, and 24 concordance in genotype (GT) 1 HCV patients receiving interferon (IFN)\u2010free treatment with the HCV NS3\/4A protease inhibitor BI 201335 and the NS5B polymerase inhibitor BI 207127","author":"Zeuzem S","year":"2012","journal-title":"Hepatology"},{"key":"e_1_2_6_1_304_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1208809"},{"key":"e_1_2_6_1_305_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60159-3"},{"key":"e_1_2_6_1_306_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61795-5"},{"key":"e_1_2_6_1_307_1","doi-asserted-by":"publisher","DOI":"10.7326\/M15-0785"},{"issue":"2","key":"e_1_2_6_1_308_1","first-page":"S264","article-title":"C\u2010SURFER: grazoprevir plus elbasvir in treatment\u2010naive and treatment\u2010experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease","volume":"62","author":"Roth D","year":"2015","journal-title":"J Hepatol"},{"key":"e_1_2_6_1_309_1","unstructured":"Merck. Merck receives FDA approval of Zepatier\u2122 (elbasvir and grazoprevir) for the treatment of chronic hepatitis C virus genotype 1 or 4 infection in adults following priority review.http:\/\/investors.merck.com\/news\/press\u2010release\u2010details\/2016\/Merck\u2010Receives\u2010FDA\u2010Approval\u2010of\u2010ZEPATIER\u2010elbasvir\u2010and\u2010grazoprevir\u2010for\u2010the\u2010Treatment\u2010of\u2010Chronic\u2010Hepatitis\u2010C\u2010Virus\u2010Genotype\u20101\u2010or\u20104\u2010Infection\u2010in\u2010Adults\u2010Following\u2010Priority\u2010Review\/default.aspx(2016)."},{"key":"e_1_2_6_1_310_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.03.039"},{"key":"e_1_2_6_1_311_1","first-page":"23","article-title":"SURVEYOR\u2010II, part 4: glecaprevir\/pibrentasvir demonstrates high SVR rates in patients with HCV genotype 2, 4, 5, or 6 infection without cirrhosis following an 8\u2010week treatment duration","author":"Hassanein T","year":"2016","journal-title":"In Vitro"},{"key":"e_1_2_6_1_312_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(17)30432-4"},{"key":"e_1_2_6_1_313_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(17)30444-0"},{"issue":"1","key":"e_1_2_6_1_314_1","article-title":"Endurance\u20104: efficacy and safety of ABT\u2010493\/ABT\u2010530 treatment in patients with chronic HCV genotype 4, 5, or 6 infection","volume":"63","author":"Asselah T","year":"2016","journal-title":"Hepatology"},{"key":"e_1_2_6_1_315_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(17)30326-4"},{"key":"e_1_2_6_1_316_1","unstructured":"KowdleyK V ColomboM ZadeikisN MantryPS CalinasF AguilarHENDURANCE\u20102: safety and efficacy of glecaprevir\/pibrentasvir in hepatitis C virus genotype 2\u2010infected patients without cirrhosis: a randomized doubleblind placebo\u2010controlled study. In: The Liver Meeting Boston MA.2016."},{"key":"e_1_2_6_1_317_1","first-page":"12","article-title":"ENDURANCE\u20101: a phase 3 evaluation of the efficacy and safety of 8\u2010versus 12\u2010week treatment with glecaprevir\/pibrentasvir (formerly ABT\u2010493\/ABT\u2010530) in HCV genotype 1 infected patients with or without HIV\u20101 co\u2010infection and without cirrhosis","author":"Zeuzem S","year":"2016","journal-title":"In Vitro"},{"key":"e_1_2_6_1_318_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(17)30467-1"},{"issue":"1","key":"e_1_2_6_1_319_1","first-page":"1125A","article-title":"EXPEDITION\u20104: efficacy and safety of glecaprevir\/pibrentasvir (ABT\u2010493\/ABT\u2010530) in patients with renal impairment and chronic hepatitis C virus genotype 1\u20136 infection","volume":"64","author":"Gane E","year":"2016","journal-title":"Hepatology"},{"key":"e_1_2_6_1_320_1","unstructured":"AbbVie. AbbVie receives US FDA approval of Mavyret\u2122 (glecaprevir\/pibrentasvir) for the treatment of chronic hepatitis C in all major genotypes (GT 1\u20106) in as short as 8 weeks.https:\/\/news.abbvie.com\/news\/abbvie\u2010receives\u2010us\u2010fda\u2010approval\u2010mavyret\u2010glecaprevirpibrentasvir\u2010for\u2010treatment\u2010chronic\u2010hepatitis\u2010c\u2010in\u2010all\u2010major\u2010genotypes\u2010gt\u20101\u20106\u2010in\u2010as\u2010short\u2010as\u20108\u2010weeks.htm(2017)."},{"key":"e_1_2_6_1_321_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu700"},{"key":"e_1_2_6_1_322_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402454"},{"key":"e_1_2_6_1_323_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1316366"},{"key":"e_1_2_6_1_324_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27890"},{"key":"e_1_2_6_1_325_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402355"},{"key":"e_1_2_6_1_326_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501315"},{"key":"e_1_2_6_1_327_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)70050-2"},{"key":"e_1_2_6_1_328_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1512610"},{"key":"e_1_2_6_1_329_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1512612"},{"key":"e_1_2_6_1_330_1","unstructured":"Gilead Sciences Inc. US food and drug administration approves gilead\u2019s Epclusa\u00ae(sofosbuvir\/elpatasvir) for the treatment of all genotypes of chronic hepatitis C.http:\/\/www.gilead.com\/news\/press\u2010releases\/2016\/6\/us\u2010food\u2010and\u2010drug\u2010administration\u2010approves\u2010gileads\u2010epclusa\u2010sofosbuvirvelpatasvir\u2010for\u2010the\u2010treatment\u2010of\u2010all\u2010genotypes\u2010of\u2010chronic\u2010hepatitis\u2010c"},{"key":"e_1_2_6_1_331_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.3860"},{"key":"e_1_2_6_1_332_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.04.045"},{"key":"e_1_2_6_1_333_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402338"},{"key":"e_1_2_6_1_334_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402869"},{"key":"e_1_2_6_1_335_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.10.005"},{"key":"e_1_2_6_1_336_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28877"},{"key":"e_1_2_6_1_337_1","unstructured":"Gilead Sciences Inc. Gilead announces SVR12 rates from four phase 3 studies of a once\u2010daily fixed\u2010dose combination of sofosbuvir velpatasvir and voxilaprevir in treatment\u2010na\u00efve and treatment\u2010experienced genotype 1\u20106 chronic HCV\u2010infected patients.http:\/\/www.gilead.com\/news\/press-releases\/2016\/10\/gilead-announces-svr12-rates-from-four-phase-3-studies-of-a-oncedaily-fixeddose-combination-of-sofosbuvir-velpatasvir-and-voxilaprevir-in-treatmentna\u00efve-and-treatmentexperienced-genotype-16-chronic-hcvinfe(2016)."},{"key":"e_1_2_6_1_338_1","unstructured":"Gilead Sciences Inc. US food and drug administration approves gilead\u2019s Vosevi\u2122 (sofosbuvir\/velpatasvir\/voxilaprevir) for re\u2010treatment of adults with chronic hepatitis C virus.http:\/\/www.gilead.com\/news\/press\u2010releases\/2017\/7\/us\u2010food\u2010and\u2010drug\u2010administration\u2010approves\u2010gileads\u2010vosevi\u2010sofosbuvirvelpatasvirvoxilaprevir\u2010for\u2010retreatment\u2010of\u2010adults\u2010with\u2010chronic\u2010hepatitis\u2010c\u2010virus"},{"key":"e_1_2_6_1_339_1","first-page":"38A","article-title":"Evaluation of the efficacy and tolerability of JNJ\u20104178 (AL\u2010335, odalasvir, and simeprevir) in hepatitis C virus\u2010infected patients without cirrhosis: The Phase IIb OMEGA\u20101 study","author":"Zeuzem S","year":"2017","journal-title":"Hepatology"},{"key":"e_1_2_6_1_340_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(17)30159-0"},{"key":"e_1_2_6_1_341_1","first-page":"315","article-title":"Efficacy and safety of the fixed\u2010dose combination regimen of grazoprevir\/ruzasvir\/uprifosbuvir (MK\u20103682) with or without ribavirin in non\u2010cirrhotic or cirrhotic participants with chronic HCV GT1, 2, 3, 4, or 6 infection (Parts A & B of C\u2010CREST\u20101 & 2)","author":"Lawitz E","year":"2017","journal-title":"Ethnicity"},{"issue":"1","key":"e_1_2_6_1_342_1","doi-asserted-by":"crossref","first-page":"S306","DOI":"10.1016\/S0168-8278(17)30931-5","article-title":"High sustained virologic response rates in patients with chronic hepatitis C virus GT1, 2 or 3 infection following 16 weeks of MK\u20103682\/grazoprevir\/ruzasvir plus ribavirin after having failed 8 weeks of a triplet drug regimen (Part C of C\u2010CREST\u20101 & 2)","volume":"66","author":"Serfaty L","journal-title":"J Hepatol"},{"key":"e_1_2_6_1_343_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.07.022"},{"key":"e_1_2_6_1_344_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1209026"},{"key":"e_1_2_6_1_345_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2011.01.003"},{"key":"e_1_2_6_1_346_1","volume-title":"Guidelines for the screening, care and treatment of persons with hepatitis C infection","author":"World Health Organization","year":"2014"},{"key":"e_1_2_6_1_347_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3009185"},{"key":"e_1_2_6_1_348_1","doi-asserted-by":"publisher","DOI":"10.4161\/hv.5.3.6614"},{"key":"e_1_2_6_1_349_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2005.02919.x"},{"key":"e_1_2_6_1_350_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.91.4.1294"},{"key":"e_1_2_6_1_351_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jir423"},{"key":"e_1_2_6_1_352_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00705-012-1564-8"},{"key":"e_1_2_6_1_353_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0104606"},{"key":"e_1_2_6_1_354_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0037054"},{"key":"e_1_2_6_1_355_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.447"},{"key":"e_1_2_6_1_356_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3003155"},{"key":"e_1_2_6_1_357_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.02.058"},{"key":"e_1_2_6_1_358_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.06.009"},{"key":"e_1_2_6_1_359_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543776.2012.673589"}],"container-title":["Medicinal Research Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmed.21554","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/med.21554","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/med.21554","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/med.21554","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T08:02:47Z","timestamp":1775289767000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/med.21554"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,2]]},"references-count":358,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["10.1002\/med.21554"],"URL":"https:\/\/doi.org\/10.1002\/med.21554","archive":["Portico"],"relation":{},"ISSN":["0198-6325","1098-1128"],"issn-type":[{"value":"0198-6325","type":"print"},{"value":"1098-1128","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,2]]},"assertion":[{"value":"2018-05-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-10-11","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-12-02","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}